Abstracts

Filters

Clear Filters
All Days Sun, Sep 28 Mon, Sep 29 Tue, Sep 30 Wed, Oct 01

Tuesday, September 30

2:50 PM - 3:00 PM PT

336 - An Explainable Deep Model for Risk Scoring and Accurate Radionecrosis Identification Following Brain Metastasis Stereotactic Radiosurgery
Speaker: Zhao, Jingtong, MS, BS - Duke University, Durham, NC
2:50 PM - 3:00 PM PT

LBA 10 - Two-year toxicity outcomes from PACE-C: Stereotactic Body Radiotherapy (SBRT) versus moderate hypofractionated radiotherapy (MHRT)
Speaker: Ratnakumaran, Ragu, MBBS - Royal Marsden NHS Foundation Trust, Sutton, London
3:00 PM - 3:10 PM PT

332 - Differential Impact of Total Body Irradiation- vs. Chemotherapy-Based Myeloablative Conditioning on Oral Microbiota and Mucositis after Allogeneic Transplantation
Speaker: Ebadi, Maryam, MD - University of Washington, Seattle, WA
3:00 PM - 3:10 PM PT

337 - Independent External Validation of Radiation-Induced Esophagitis Prediction during Chemoradiation Therapy for NSCLC Using RTOG 0617 Trial Data
Speaker: Cella, Laura, PhD - National Research Council (IBB), Napoli, Campania
3:00 PM - 3:10 PM PT

LBA 11 - Addition of Metastasis-Directed Therapy to Standard of Care: Primary Aggregate Analysis and Immunologic Correlatives of the Phase II Randomized EXTEND Trial
Speaker: Sherry, Alexander, MD - Mayo Clinic Rochester, Rochester, MN
3:10 PM - 3:20 PM PT

333 - Updated Results of RESTART Protocol (<em>R</em>adioth<em>E</em>rapy bridging and con<em>S</em>olida<em>T</em>ion for C<em>AR-T</em>) in Large B-cell Lymphoma
Speaker: Mikhaeel, George, MD, MBBS - Guy's and St. Thomas' NHS Foundation Trust, London, London
3:10 PM - 3:20 PM PT

338 - Interpretable Deep Learning Predicts Metastasis-Free Survival (MFS) from Conventional Imaging for Oligometastatic Castration-Sensitive Prostate Cancer (omCSPC) Using Multi-Modality PSMA PET and CT Imaging
Speaker: Cao, Yufeng, PhD - University of Maryland Central Maryland Radiation Oncology, Columbia, MD
3:10 PM - 3:20 PM PT

LBA 12 - Neoadjuvant Chemotherapy with Trastuzumab with or without Concurrent Radiotherapy in HER2-Positive Inoperable Locally Advanced Breast Cancer: A Phase 2 Randomized Trial (NEOTRAC)
Speaker: Iyer, Priya, MD, MBBS - Cancer Institute (WIA), CHENNAI, Tamil Nadu
3:20 PM - 3:30 PM PT

339 - 3D topological analysis for assessing therapeutic responses to radiation and chemotherapy with and without anti-CD40 immunotherapy in local advanced rectal cancer
Speaker: Peng, Hao, PhD - UT Southwestern Medical Center, Dallas, TX
3:20 PM - 3:30 PM PT

LBA 13 - Baseline and Time-Dependent Predictors of Cognitive Decline for Brain Metastasis Patients Treated with Radiotherapy- A Secondary Analysis of the ATHENA Trial
Speaker: Perlow, Haley, MD - Case Western Reserve University/University Hospitals Cleveland Medical Center, Cleveland, OH
3:30 PM - 3:40 PM PT

340 - Radiotherapy-Induced Acute Lymphopenia for Low and Intermediate Risk Prostate Cancer
Speaker: Moteabbed, Maryam, PhD - Massachusetts General Hospital, Boston, MA
3:30 PM - 3:40 PM PT

LBA 14 - Neoadjuvant and Adjuvant Pembrolizumab (Pembro) Plus Standard of Care (SOC) in Resectable Locally Advanced Head and Neck Squamous Cell Carcinoma (LA HNSCC): Postoperative Risk Subgroup Analysis of KEYNOTE-689
Speaker: Lee, Nancy, MD, FASTRO - Memorial Sloan Kettering Cancer Center, New York, NY